Based on the findings implicating increased mTOR signaling in High-OXPHOS MBMs, we evaluated the clinical efficacy of AZD2014, a mTORC1/2 inhibitor previously shown to completely ablate mTOR signaling and synergize with MEKi in subcutaneous High-OXPHOS melanoma xenografts.9 Mice bearing intrancranial xenografts of the High-OXPHOS A375-R1 cell line were randomized to treatment with AZD2014 (20 mg/kg p.o. once daily) or vehicle control. The gene discussed is MTOR; the disease is melanoma.